Previous Page  10 / 19 Next Page
Information
Show Menu
Previous Page 10 / 19 Next Page
Page Background

Gastro Education 2018

Journal of Clinical Gastroenterology and Hepatology

ISSN: 2575-7733

Page 24

September 06-07, 2018

London, UK

14

th

International Conference on

Gastro Education

Introduction:

Hepatocellular carcinoma (HCC) is a cancer

with high mortality. HCC treatment including surgical and loco

regional treatment. Recent studies focus on the role of immune

system thus immunotherapy represent novel approach to treat

HCC because of its immunological characteristic. Curcumin and

taurine have been used to participate in HCC through activation

of immune system.

Materials & Methods:

Mononuclear leukocytes and serum were

obtained from HCC patients (n=15) baseline then treated oral

with curcumin and taurine after three weeks, and six weeks and

healthy control (n=30). IL-10, IL-6, IL-8, TNF-α, IFN-γ and TGF-α

by ELISA technique and CD4+%, CD8+%, CD4+CD25+%, and

CD8+CD25+% by flow cytometery were determined.

Results:

Results revealed that after treatment for IL-10 there

was significant decrease (P<0.05), but for IFN-γ there was

significant increase (P<0.01). On contrast, levels of IL-6, IL-8,

TNF-α, and TGF-α there were no significant difference (P>0.05).

For CD4+%, CD8+%, CD4+CD25+%, and CD8+CD25+% there

were significant differences (P<0.0001, P<0.001, P<0.01, and

P<0.00001 respectively) compared to baseline.

Conclusion:

Curcumin and taurine have a protective role against

hepatocarcinogenesis.

Biography

Farid Kashwaa pursued his PhD Degree from Ain Shams University and

Postdoctoral studies fromNational Cancer Institute of Cairo University, Egypt

respectively. He is curently a Full Professor of Medical Biochemistry at the

same institute since 2011. He has published 25 papers in reputed journals

and has been serving as an Editorial Board Member of repute.

kashwaa56@yahoo.com

Enhanced prophylactic and therapeutic potential of curcumin

and taurine on hepatocellular carcinoma

Farid Kashwaa

National Cancer Institute - Cairo University, Egypt

Farid Kashwaa, J Clin Gastroenterol Hepatol 2018, Volume 2

DOI: 10.21767/2575-7733-C2-005